PT3255061T - Imunodepleção seletiva de nicho de células estaminais endógenas para enxerto - Google Patents
Imunodepleção seletiva de nicho de células estaminais endógenas para enxertoInfo
- Publication number
- PT3255061T PT3255061T PT171680218T PT17168021T PT3255061T PT 3255061 T PT3255061 T PT 3255061T PT 171680218 T PT171680218 T PT 171680218T PT 17168021 T PT17168021 T PT 17168021T PT 3255061 T PT3255061 T PT 3255061T
- Authority
- PT
- Portugal
- Prior art keywords
- immunodepletion
- engraftment
- selective
- stem cell
- cell niche
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85643506P | 2006-11-03 | 2006-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3255061T true PT3255061T (pt) | 2021-07-26 |
Family
ID=39468595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT171680218T PT3255061T (pt) | 2006-11-03 | 2007-11-02 | Imunodepleção seletiva de nicho de células estaminais endógenas para enxerto |
Country Status (9)
Country | Link |
---|---|
US (4) | US20100226927A1 (pt) |
EP (3) | EP3255061B1 (pt) |
DK (1) | DK2088864T3 (pt) |
ES (2) | ES2882360T3 (pt) |
HU (1) | HUE034583T2 (pt) |
PL (1) | PL3255061T3 (pt) |
PT (1) | PT3255061T (pt) |
SI (1) | SI3255061T1 (pt) |
WO (1) | WO2008067115A2 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3255061B1 (en) | 2006-11-03 | 2021-06-16 | The Board of Trustees of the Leland Stanford Junior University | Selective immunodepletion of endogenous stem cell niche for engraftment |
EP3763740A1 (en) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
US20140329314A1 (en) * | 2011-03-29 | 2014-11-06 | Christopher O'Sullivan | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
SG11201508027PA (en) * | 2013-02-28 | 2015-11-27 | Harvard College | Methods and compositions for mobilizing stem cells |
EP3145543A4 (en) | 2014-05-23 | 2017-12-13 | Celldex Therapeutics, Inc. | Treatment of eosinophil or mast cell related disorders |
EP4257145A3 (en) | 2014-08-26 | 2023-10-18 | The Board of Trustees of the Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
US10889646B2 (en) | 2015-03-25 | 2021-01-12 | Children's Hospital Medical Center | Use of KIT inhibitors to condition subjects for a hematopoietic stem cell (HSC) transplantation |
AU2016246707B2 (en) * | 2015-04-06 | 2021-03-25 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
EA039364B1 (ru) * | 2015-10-09 | 2022-01-18 | Президент Энд Феллоус Оф Гарвард Колледж | Композиции и способы для немиелоаблативного кондиционирования |
US9957576B2 (en) | 2016-04-21 | 2018-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
KR20230066647A (ko) | 2016-06-17 | 2023-05-16 | 마젠타 테라퓨틱스 인코포레이티드 | Cd117+ 세포의 고갈을 위한 조성물 및 방법 |
WO2017219025A1 (en) * | 2016-06-17 | 2017-12-21 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
EP3526260A4 (en) * | 2016-10-13 | 2020-11-18 | President and Fellows of Harvard College | NON-MYELOABLATIVE PACKAGING COMPOSITIONS AND METHODS |
FI3535392T3 (fi) * | 2016-11-02 | 2024-05-23 | Univ Basel | Immunologisesti havaittavia solupintavariantteja käytettäväksi soluterapiassa |
JOP20190155A1 (ar) * | 2016-12-21 | 2019-06-23 | Novartis Ag | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم |
EP3570850A4 (en) * | 2017-01-18 | 2020-10-14 | Thalia Papayannopoulou | COMPOSITIONS AND PROCEDURES FOR CONDITIONING TRANSPLANT RECIPIENTS |
WO2018134787A2 (en) | 2017-01-20 | 2018-07-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
AU2018213397A1 (en) * | 2017-01-30 | 2019-07-25 | The Board Of Trustees Of The Leland Stanford Junior University | A non-genotoxic conditioning regimen for stem cell transplantation |
US11744861B2 (en) | 2017-03-13 | 2023-09-05 | Poseida Therapeutics, Inc. | Compositions and methods for selective elimination and replacement of hematopoietic stem cells |
MX2020004140A (es) * | 2017-10-24 | 2020-08-13 | Magenta Therapeutics Inc | Composiciones y metodos para la eliminacion de celulas cd117+. |
JP2021500391A (ja) | 2017-10-24 | 2021-01-07 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | Cd117+細胞を減少させるための組成物及び方法 |
US11642379B2 (en) | 2017-12-08 | 2023-05-09 | The Board Of Trustees Of The Leland Stanford Junior University | Hematopoietic stem cell engraftment |
UY38265A (es) * | 2018-06-20 | 2020-01-31 | Novartis Ag | Conjugados anticuerpo droga para ablación de células madre hematopoyéticas |
US11208482B2 (en) | 2018-11-26 | 2021-12-28 | Forty Seven, Inc. | Humanized antibodies against c-Kit |
EP3886869A4 (en) * | 2018-11-28 | 2022-07-06 | Forty Seven, Inc. | GENETICALLY MODIFIED CSPH RESISTANT TO ABLATIVE TREATMENT |
WO2020219775A1 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anti-cd117 antibody-drug conjugates and uses thereof |
IL311590A (en) * | 2021-10-04 | 2024-05-01 | Us Health | Bivalent anti-CMPL SCFV and its uses |
WO2023183555A1 (en) * | 2022-03-25 | 2023-09-28 | Memorial Sloan-Kettering Cancer Center | Method of promoting thymic recovery by administering hematopoietic stem cells with low c-kit expression |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69226431T2 (de) | 1991-04-05 | 1999-04-22 | Univ Washington | Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor |
GB9323199D0 (en) | 1993-11-10 | 1994-01-05 | Falkenberg J H F | Leukaemia treatment |
AU734089B2 (en) | 1996-10-01 | 2001-06-07 | Geron Corporation | Human telomerase catalytic subunit |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
US7468277B2 (en) | 1999-12-23 | 2008-12-23 | Cornell Research Foundation, Inc. | Enriched preparation of human fetal multipotential neural stem cells |
CA2895884C (en) * | 2000-03-06 | 2019-04-23 | University Of Kentucky Research Foundation | A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells |
JP4130179B2 (ja) | 2001-09-27 | 2008-08-06 | ノバルティス アクチエンゲゼルシャフト | 骨髄腫を処置するためのc−kit阻害剤の使用 |
US20030099621A1 (en) * | 2001-11-29 | 2003-05-29 | Robert Chow | Stem cell screening and transplantation therapy for HIV infection |
AU2003245752A1 (en) | 2002-06-28 | 2004-01-19 | Bio Transplant, Inc. | Process for promoting graft acceptance by depletion of hematopoietic stem cells |
WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
EP3255061B1 (en) | 2006-11-03 | 2021-06-16 | The Board of Trustees of the Leland Stanford Junior University | Selective immunodepletion of endogenous stem cell niche for engraftment |
-
2007
- 2007-11-02 EP EP17168021.8A patent/EP3255061B1/en active Active
- 2007-11-02 ES ES17168021T patent/ES2882360T3/es active Active
- 2007-11-02 PT PT171680218T patent/PT3255061T/pt unknown
- 2007-11-02 HU HUE07871350A patent/HUE034583T2/en unknown
- 2007-11-02 ES ES07871350.0T patent/ES2642205T3/es active Active
- 2007-11-02 EP EP21179294.0A patent/EP3960764A1/en active Pending
- 2007-11-02 EP EP07871350.0A patent/EP2088864B1/en active Active
- 2007-11-02 SI SI200732179T patent/SI3255061T1/sl unknown
- 2007-11-02 DK DK07871350.0T patent/DK2088864T3/en active
- 2007-11-02 PL PL17168021T patent/PL3255061T3/pl unknown
- 2007-11-02 US US12/447,634 patent/US20100226927A1/en not_active Abandoned
- 2007-11-02 WO PCT/US2007/083529 patent/WO2008067115A2/en active Application Filing
-
2016
- 2016-07-15 US US15/211,679 patent/US10072091B2/en active Active
-
2018
- 2018-07-13 US US16/035,187 patent/US20180327507A1/en not_active Abandoned
-
2022
- 2022-12-22 US US18/087,618 patent/US11905333B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2642205T3 (es) | 2017-11-15 |
WO2008067115A3 (en) | 2008-11-06 |
EP2088864B1 (en) | 2017-08-16 |
EP2088864A4 (en) | 2010-09-29 |
EP3255061A1 (en) | 2017-12-13 |
PL3255061T3 (pl) | 2021-12-06 |
US20230128340A1 (en) | 2023-04-27 |
EP2088864A2 (en) | 2009-08-19 |
ES2882360T3 (es) | 2021-12-01 |
US20100226927A1 (en) | 2010-09-09 |
EP3255061B1 (en) | 2021-06-16 |
HUE034583T2 (en) | 2018-02-28 |
US10072091B2 (en) | 2018-09-11 |
WO2008067115A2 (en) | 2008-06-05 |
US20180327507A1 (en) | 2018-11-15 |
US11905333B2 (en) | 2024-02-20 |
EP3960764A1 (en) | 2022-03-02 |
SI3255061T1 (sl) | 2021-09-30 |
DK2088864T3 (en) | 2017-10-02 |
US20170066834A1 (en) | 2017-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI3255061T1 (sl) | Selektivno imunsko osiromašenje niše endogenih matičnih celic za vsaditev | |
EP2094839A4 (en) | EXPANSION OF HEMATOPOIETIC STEM CELLS | |
ZA200809978B (en) | Method for selection of transformed cells | |
IL205951A0 (en) | Method of inhibition of leukemic stem cells | |
GB2458863B (en) | Improved culture of stem cells | |
GB2440690B (en) | Sealing structure of refrigerator | |
SG138570A1 (en) | Growth of embryonic stem cells | |
ZA201001158B (en) | Diferentiation of human embryonic stem cells | |
IL196884A0 (en) | Tumor suppression using placental stem cells | |
FI2073842T4 (fi) | Ihmisen myeloidileukemiaperäisten solujen käyttö vasta-aineiden ekspressoimiseksi | |
GB0600972D0 (en) | Enrichment of cells | |
HUE054629T2 (hu) | Akkumulátor teljesítménykorlátainak prediktív meghatározása | |
EP2079832A4 (en) | ISOLATION AND PURIFICATION OF HEMATOPOIETIC STEM CELLS FROM LIPOSUCCION ASPIRATES | |
EP2069477A4 (en) | CHEMOREPULSION OF CELLS | |
EP2214481A4 (en) | PROCESS FOR INCREASING THE PERFORMANCE OF LATE FOLLOW-UP | |
EP1917348A4 (en) | ISOLATION OF MULTIPLE LINE STEM CELLS | |
EP2038402A4 (en) | DEVICES AND METHODS FOR CRYOPRESERVATION OF CELLS | |
EP2223026A4 (en) | REFRIGERATOR ICE MANUFACTURING ASSEMBLY | |
EP1993477A4 (en) | TRANSPLANTATION OF NERVE CELLS | |
GB0705854D0 (en) | Methods of construction | |
ZA200901912B (en) | Use of human cells of myeloid leukaemia origin for expression of antibodies | |
EP2022846A4 (en) | METHOD FOR ISOLATING A STEM CELL | |
EP1954801A4 (en) | METHOD FOR ISOLATING CELLS | |
EP2037960A4 (en) | METHOD FOR MANIPULATING STEM CELLS | |
TWM299804U (en) | Structure of leak-proof valve |